Sign In
Buy RARE
$22.41
+0.630 (+2.89%)
At Close: Jun 03, 2026
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 20'th Dec 2024
NOVATO, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rar
RARE Submits BLA to the FDA for Sanfilippo Syndrome Gene Therapy
12:31pm, Friday, 20'th Dec 2024
Ultragenyx submits a BLA to the FDA seeking the accelerated approval of UX111 for patients with Sanfilippo syndrome type A in the United States.
LONDON, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialisation of novel therapies for rare and ul
Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome
04:05pm, Thursday, 19'th Dec 2024
Company on track to initiate the Aurora study to evaluate GTX-102 in other Angelman syndrome genotypes and in other age groups in 2025 Company on track to initiate the Aurora study to evaluate GTX-102
HARMONY BIOSCIENCES TO PARTICIPATE IN OPPENHEIMER MOVERS IN RARE DISEASE SUMMIT
08:05am, Tuesday, 03'rd Dec 2024
PLYMOUTH MEETING, Pa. , Dec. 3, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the upcomi
Ultragenyx to Participate in Investor Conferences in December
04:30pm, Tuesday, 26'th Nov 2024
NOVATO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for ser
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Wednesday, 20'th Nov 2024
NOVATO, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rar
AMGEN PRESENTS NEW DATA ACROSS RARE INFLAMMATORY DISEASES AT ACR 2024
04:00pm, Thursday, 14'th Nov 2024
MITIGATE Phase 3 Study Results Reinforce Promise of UPLIZNA® as the First Potential Treatment tor IgG4-RD Phase 4 AGILE Data Support Shortening KRYSTEXXA® Infusion Time THOUSAND OAKS, Calif. , Nov.
Ultragenyx: Ready For More Growth After Q3 Earnings Beat
11:12am, Tuesday, 12'th Nov 2024
Ultragenyx's strong Q3 earnings report, with a 42% YoY revenue increase, has reignited my interest in initiating a starter position in RARE. The company's promising pipeline, including late-stage prog
Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST's 17th Annual Global Science Summit
10:30am, Saturday, 09'th Nov 2024
Phase 1/2 data show improvements across all domains and confirm that Phase 3 Aspire study is amply powered to establish efficacy of GTX-102
Ultragenyx Q3 Loss Narrower Than Expected, Revenues Beat Estimates
10:45am, Wednesday, 06'th Nov 2024
RARE reports encouraging third-quarter results, beating earnings and revenue estimates. Product sales increase year over year.
Ultragenyx Pharmaceutical Inc. (RARE) Q3 2024 Earnings Call Transcript
10:40pm, Tuesday, 05'th Nov 2024
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE ) Q3 2024 Earnings Conference Call November 5, 2024 5:00 PM ET Company Participants Joshua Higa - VP, IR Emil Kakkis - CEO and President Erik Harris - CCO H
Compared to Estimates, Ultragenyx (RARE) Q3 Earnings: A Look at Key Metrics
07:00pm, Tuesday, 05'th Nov 2024
While the top- and bottom-line numbers for Ultragenyx (RARE) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics co
Ultragenyx (RARE) Reports Q3 Loss, Tops Revenue Estimates
06:15pm, Tuesday, 05'th Nov 2024
Ultragenyx (RARE) came out with a quarterly loss of $1.40 per share versus the Zacks Consensus Estimate of a loss of $1.45. This compares to loss of $2.23 per share a year ago.
Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate Update
04:01pm, Tuesday, 05'th Nov 2024
Third quarter 2024 total revenue grew 42% versus prior year to $139 million, including Crysvita® revenue of $98 million and Dojolvi® revenue of $21 million
